Table 3.
Comparison of the occurrence of hypoglycaemia and gastrointestinal symptoms between propensity score matched injectable‐naive exenatide once weekly and basal insulin initiators, by age and renal function
| Characteristic | N | Number of events (%) | IR per 1000 person‐years (95% CI) | Relative rate (95% CI) | |
|---|---|---|---|---|---|
| Hypoglycaemia | |||||
| 18‐64 years | EQW | 1513 | 101 (6.7) | 46.5 (37.8‐56.5) | 0.75 (0.60‐0.95) |
| BI | 3064 | 262 (8.6) | 61.6 (54.3‐69.5) | Reference | |
| ≥65 years | EQW | 495 | 48 (9.7) | 72.1 (53.2‐95.6) | 0.92 (0.65‐1.29) |
| BI | 952 | 106 (11.1) | 78.5 (64.3‐95.0) | Reference | |
| Nausea and vomiting | |||||
| 18‐64 years | EQW | 1513 | 257 (17.0) | 130.0 (114.6‐146.9) | 1.13 (0.97‐1.32) |
| BI | 3064 | 467 (15.2) | 115.0 (104.8‐126.0) | Reference | |
| ≥65 years | EQW | 495 | 83 (16.8) | 133.8 (106.5‐165.8) | 1.45 (1.09‐1.91) |
| BI | 952 | 123 (12.9) | 92.5 (76.9‐110.3) | Reference | |
| Constipation and diarrhoea | |||||
| 18‐64 years | EQW | 1513 | 257 (17.0) | 130.1 (114.7‐147.0) | 1.11 (0.96‐1.30) |
| BI | 3064 | 470 (15.3) | 116.7 (106.4‐127.8) | Reference | |
| ≥65 years | EQW | 495 | 108 (21.8) | 181.8 (149.2‐219.5) | 1.21 (0.96‐1.54) |
| BI | 952 | 186 (19.5) | 150.0 (129.2‐173.2) | Reference | |
| Any gastrointestinal symptom | |||||
| 18‐64 years | EQW | 1513 | 386 (25.5) | 212.1 (191.5‐234.4) | 1.13 (1.00‐1.28) |
| BI | 3064 | 704 (23.0) | 187.0 (173.4‐201.3) | Reference | |
| ≥65 years | EQW | 495 | 148 (29.9) | 270.1 (228.3‐317.3) | 1.32 (1.08‐1.63) |
| BI | 952 | 242 (25.4) | 203.9 (179.0‐231.3) | Reference | |
| Hypoglycaemia | |||||
| Normal function | EQW | 924 | 60 (6.5) | 44.9 (34.3‐57.8) | 0.75 (0.56‐1.01) |
| BI | 1873 | 159 (8.5) | 60.1 (51.1‐70.1) | Reference | |
| RI | EQW | 1022 | 84 (8.2) | 59.2 (47.2‐73.3) | 0.81 (0.63‐1.05) |
| BI | 2030 | 204 (10.0) | 72.8 (63.2‐83.6) | Reference | |
| Nausea and vomiting | |||||
| Normal function | EQW | 924 | 165 (17.9) | 136.7 (116.7‐159.2) | 1.21 (1.00‐1.46) |
| BI | 1873 | 286 (15.3) | 113.4 (100.6‐127.3) | Reference | |
| RI | EQW | 1022 | 166 (16.2) | 126.3 (107.8‐147.1) | 1.19 (0.98‐1.43) |
| BI | 2030 | 290 (14.3) | 106.6 (94.6‐119.6) | Reference | |
| Constipation and diarrhoea | |||||
| Normal function | EQW | 924 | 166 (18.0) | 139.0 (118.7‐161.9) | 1.28 (1.05‐1.55) |
| BI | 1873 | 273 (14.6) | 109.0 (96.5‐122.7) | Reference | |
| RI | EQW | 1022 | 194 (19.0) | 150.2 (129.8‐172.9) | 1.06 (0.89‐1.26) |
| BI | 2030 | 371 (18.3) | 141.8 (127.8‐157.0) | Reference | |
| Any gastrointestinal symptom | |||||
| Normal function | EQW | 924 | 254 (27.5) | 231.2 (203.6‐261.4) | 1.28 (1.09‐1.49) |
| BI | 1873 | 422 (22.5) | 180.8 (164.0‐198.9) | Reference | |
| RI | EQW | 1022 | 268 (26.2) | 223.9 (197.9‐252.3) | 1.11 (0.95‐1.28) |
| BI | 2030 | 502 (24.7) | 202.3 (185.0‐220.8) | Reference | |
BI, basal insulin; CI, confidence interval; EQW, exenatide once weekly; IR, incidence rate; RI, renal impairment.